Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25290733 | 1.00 | CTSL (0.59) | CTSLCTSBCTSS | |
| SCHEMBL25290734 | 1.00 | CTSL (0.59) | CTSLCTSBCTSS | |
| SCHEMBL29461460 | 1.00 | CTSL (0.59) | CTSLCTSBCTSS | |
| SCHEMBL27411971 | 1.00 | CTSL (0.59) | CTSLCTSBCTSS | |
| SCHEMBL24425348 | 1.00 | CTSL (0.59) | CTSLCTSBCTSS | |
| SCHEMBL23721348 | 0.99 | CTSL (0.59) | CTSLCTSBCTSS | |
| SCHEMBL26452477 | 0.93 | CTSL (0.52) | CTSLCTSBCTSS | |
| SCHEMBL23722570 | 0.93 | CTSL (0.52) | CTSLCTSBCTSS | |
| SCHEMBL25766890 | 0.93 | CTSB (0.57) | CTSLCTSBCTSS | |
| SCHEMBL23722297 | 0.93 | CTSL (0.55) | CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | FRONTIER BIOTECHNOLOGIES INC. (CN) | 2023-05-04 | — | — | US | claimed |
| WO-2024149990-A1 | NIRMATRELVIR ANALOGS AS 3C LIKE PROTEASE INHIBITORS FOR TREATING VIRAL INFECTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | FRONTIER BIOTECHNOLOGIES INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | FRONTIER BIOTECHNOLOGIES INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4166539-A1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-11541034-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-4098653-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-11452711-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-11351149-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2021250648-A1 | NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | PFIZER INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021151265-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | CTSL 1/4885CTSB 8/4885CTSS 3/4885 |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885CTSS 45/4885 |
| US-11452711-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CTSB 657/4885CTSS 1307/4885 |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CTSB 657/4885CTSS 1307/4885 |
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | ACE, ACE2, TMPRSS2 | CTSL 15/4885CTSB 127/4885CTSS 73/4885 |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | ACE2, ACE, TMPRSS2 | CTSL 26/4885CTSB 27/4885CTSS 28/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885CTSS 45/4885 |
| US-11541034-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CTSB 657/4885CTSS 1307/4885 |
| US-11351149-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CTSB 657/4885CTSS 1307/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885CTSS 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.